

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING  
REJECTION OVER A PENDING "REFERENCE" APPLICATION**Docket Number (Optional)  
17243/003001

In re Application of: Melwyn Abreo et al.

Application No.: 10/566,193-Conf. #5685

Filed: January 30, 2006

For: PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

The owner\*, Xenon Pharmaceuticals Inc., of 100  
percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of  
any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any

10/567,009 and

patent granted on pending reference Application Numbers 10/566,857, filed on January 30, 2006,  
as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference applications may  
be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference applications. The  
owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period  
that it and any patent granted on the reference applications are commonly owned. This agreement runs with any patent  
granted on the instant application and is binding upon the grantee, its successors or assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that  
would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said  
reference applications, "as the term of any patent granted on said reference applications may be shortened by any terminal  
disclaimer filed prior to the grant of any patent on the pending reference applications," in the event that: any such patent: granted  
on the pending reference applications: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a  
court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims  
canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term  
as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency,  
etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on  
information and belief are believed to be true; and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United  
States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 48,885

  
Signature

August 28, 2008  
Date

T. Chyau Liang, Ph.D.  
Typed or printed name

(713) 228-8600  
Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

**WARNING: Information on this form may become public. Credit card information should not  
be included on this form. Provide credit card information and authorization on PTO-2038.**

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  
Form PTO/SB/96 may be used for making this statement. See MPEP § 324.